trending Market Intelligence /marketintelligence/en/news-insights/trending/ylwnomx8d1ask8mhlrum0w2 content esgSubNav
In This List

Intellipharmaceutics' continued listing request granted by Nasdaq

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Intellipharmaceutics' continued listing request granted by Nasdaq

Intellipharmaceutics International Inc. said the Nasdaq Hearings Panel granted its request for continued listing while it works to regain compliance with the exchange's listing requirements.

The Toronto-based drugmaker has until Sept. 28 to comply with the Nasdaq's $1 bid price and $2.5 million stockholder's equity requirements. Intellipharmaceutics also needs to submit its updated financial projections showing it can maintain compliance.